These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12542005)

  • 21. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progress in Examination and Treatment of Hepatitis C Virus].
    Suda G; Sakamoto N
    Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future hepatitis C virus treatment: interferon-sparing combinations.
    Gane E
    Liver Int; 2011 Jan; 31 Suppl 1():62-7. PubMed ID: 21205140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatitis C therapy: a problem almost solved].
    Rizzetto M
    Recenti Prog Med; 2014 Jun; 105(6):225-6. PubMed ID: 25002283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of HCV infection with the novel NS3/4A protease inhibitors.
    De Luca A; Bianco C; Rossetti B
    Curr Opin Pharmacol; 2014 Oct; 18():9-17. PubMed ID: 25117198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simeprevir (Olysio) for chronic hepatitis C.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):1-3. PubMed ID: 24419295
    [No Abstract]   [Full Text] [Related]  

  • 28. Telaprevir-induced DRESS.
    Kesar V; Kesar V; Khaitova V; Motamed D; Schiano T
    J Drugs Dermatol; 2014 Feb; 13(2):199-200. PubMed ID: 24509972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating hepatitis C in lower-income countries.
    Jayasekera CR; Barry M; Roberts LR; Nguyen MH
    N Engl J Med; 2014 May; 370(20):1869-71. PubMed ID: 24720680
    [No Abstract]   [Full Text] [Related]  

  • 32. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
    Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
    Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 34. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 35. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
    Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
    Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
    Gao X; Stephens JM; Carter JA; Haider S; Rustgi VK
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):335-43. PubMed ID: 22812557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VX-950 (Vertex/Mitsubishi).
    Summa V
    Curr Opin Investig Drugs; 2005 Aug; 6(8):831-7. PubMed ID: 16121690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.